The newer second-generation antipsychotic drugs (Risperidone, Quetiapine, Amisulpride, Aripiprazole, Clozapine, Olanzapine) are promoted because they have a lower risk of extrapyramidal side effects than older drugs. Drug companies often promote these newer drugs as virtually free from extrapyramidal side effects, but the patients who take them and the clinicians who prescribe them often don’t agree. [read the full story…]
There is an enormous body of research concerned with schizophrenia and the use of antipsychotic drugs. A quick search on PubMed for ‘schizophrenia, antipsychotics and randomised controlled trials’ brings back nearly 2,000 articles! The authors of a new systematic review and meta analysis published today in the Lancet, suggest that one area that has not [read the full story…]
Antipsychotic drugs are currently prescribed to a significant proportion of young people who are diagnosed with psychosis. Past research has estimated that up to half of people at risk of developing psychosis at a young age will progress to a full blown psychotic illness such as schizophrenia. A new landmark randomised controlled trial has been [read the full story…]
Regular readers may recall previous blogs where I have written about the dangers associated with antipsychotic drugs in elderly patients. Many of you have responded simply and emotionally on Twitter by saying: “Stop prescribing these drugs!” Others have recognised that the issue is far from clear cut as a fair proportion of patients do have [read the full story…]
There is a great deal of debate about prescribing antipsychotics to children and young people. Prescription rates of these drugs has risen sharply over the last few years, but there remains only limited evidence about the safety and efficacy of these medicines. The second-generation antipsychotics (SGAs) have become more popular and this is partly due [read the full story…]
The public perception of mental health and violent behaviour has often been influenced by poor media coverage and a focus on specific crimes committed by people with psychosis. There’s a nice summary of work in this area on the Mind website, which includes a number of enlightening stats, including this one: The fear of random [read the full story…]
This topic has been well publicised in recent years and for good reason. We know that there is a huge disparity between the number of people with dementia who are prescribed antipsychotics (180,000 in England each year) and the number who may derive some benefit from the treatment (36,000). We also know that dangerous side [read the full story…]
Late-onset schizophrenia is relatively common. Onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. The condition is different from early-onset schizophrenia on a number of counts, including the response to antipsychotic drugs. This Cochrane review set out to assess the effects of antipsychotic drugs for elderly people with [read the full story…]
There has been concern about the rate of use of antipsychotic mecdication for people with learning disabilities for some time. We have posted a number of studies which have raised questions about efficacy and rate of use here on this blog. The authors of this study were concerned to look at prescription rates in people [read the full story…]
This new systematic review compares how effective first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are at preventing relapse in patients with schizophrenia. The authors carried out a meta-analysis of 23 randomised controlled trials that lasted for ≥6 months and compared FGAs with SGAs in schizophrenia. The outcomes they studied were: Study defined relapse Relapse at 3, [read the full story…]
